CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
创新型 ALA-CART 平台对多种癌症显示出高疗效
英文原题：An innovative ALA-CART platform exhibits high efficacy against cancers.
查看英文原题
An innovative ALA-CART platform exhibits high efficacy against cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
由于敏感性不足且持久性有限，嵌合抗原受体（CAR）T 细胞在抗原低表达肿瘤中的治疗效果受到制约。本期《Cancer Cell》中，Pham-Danis 等人设计了 ALA-CART 平台，通过在低抗原刺激后增强 LAT 磷酸化，提高 CAR-T 细胞的敏感性、持久性、分化能力和细胞毒功能。
展开英文摘要原文
The therapeutic efficacy of chimeric antigen receptor (CAR) T cells is compromised in antigen-low tumors due to poor sensitivity and insufficient persistence. In this issue of Cancer Cell, Pham-Danis et al. design the ALA-CART platform to improve CAR T cell sensitivity, persistence, differentiation, and cytotoxic function by enhancing LAT phosphorylation after low antigen stimulation.
论文信息
- 作者
- Wang J、Lin X
- 第一作者单位
- Changping Laboratory, Beijing, China.China
- 通讯作者单位
- Changping Laboratory, Beijing, China; School of Basic Medical Science, Tsinghua University School of Medicine, Beijing, China; Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China. Electronic address: linxin307@tsinghua.edu.cn.China
- 期刊
- Cancer cell2025 Mar 10
- 原文标识
- PubMed 40068592 · DOI 10.1016/j.ccell.2025.02.021